MSC 1 - Northern Biologics/Mosaic Biomedicals

Drug Profile

MSC 1 - Northern Biologics/Mosaic Biomedicals

Latest Information Update: 02 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vall d-Hebron Research Institute
  • Developer Mosaic Biomedicals; Northern Biologics
  • Class Antibodies; Antineoplastics
  • Mechanism of Action Leukaemia inhibitory factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Nov 2017 By early 2018, Northern Biologics and Mosaic Biomedicals plan a clinical trial in Cancer in Canada, Europe and USA
  • 19 Dec 2016 Celgene exercises an option to acquire certain rights to the MSC 1 programme
  • 19 Dec 2016 Preclinical trials in Cancer in Canada (Parenteral) after December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top